Form 4: LeMaitre CEO Gifts Shares, Accrues Dividend Rights

Sentiment:

Insider Transaction Report 5 September 2025 8:59 PM

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc., reported gifting 21,200 shares of common stock and accruing new dividend equivalent rights.

Summary

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular Inc. (LMAT), reported transactions on September 3 and 4, 2025.
On September 3, 2025, Mr. LeMaitre disposed of a total of 21,200 shares of common stock through gifts (Transaction Code G), with a transaction price of $0 per share.
Following these dispositions, Mr. LeMaitre directly beneficially owns 1,705,803 shares of common stock.
On September 4, 2025, Mr. LeMaitre acquired various dividend equivalent rights (DERs) totaling 45.047 units.
These DERs accrued on restricted stock unit (RSU) and performance share unit (PSU) awards granted between December 2, 2020, and December 6, 2024.
Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock and vests proportionately with the underlying awards.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (gifts and accrual of dividend equivalent rights) which are generally expected and do not indicate a significant positive or negative shift in company fundamentals or outlook. The gifting of shares reduces direct ownership but is a common practice, while DER accruals are part of compensation.

Positives

Accrual of additional Dividend Equivalent Rights (DERs) indicates ongoing participation in company performance and dividends for the CEO, aligning his interests with shareholders.

Negatives

Disposition of 21,200 shares of common stock, even if by gift, reduces the direct beneficial ownership of the Chairman and CEO.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: The gifting of shares by the CEO slightly reduces his direct beneficial ownership, which could be viewed neutrally or as a minor reduction in insider alignment, though his overall holdings remain substantial. The accrual of DERs reinforces his ongoing compensation structure tied to company performance.

Key Dates

Date	Description
12/02/2020	Grant date of a restricted stock unit award on which dividend equivalent rights accrued.
12/11/2021	Grant date of a restricted stock unit award on which dividend equivalent rights accrued.
12/12/2022	Grant date of a restricted stock unit award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued.
12/08/2023	Grant date of a restricted stock unit award and a Performance Share Unit (PSU) award on which dividend equivalent rights accrued.
12/06/2024	Grant date of a restricted stock unit award on which dividend equivalent rights accrued.
09/03/2025	Date of disposition of common stock by George W. LeMaitre.
09/04/2025	Date of acquisition of dividend equivalent rights by George W. LeMaitre.
09/05/2025	Signature date of the reporting person.

Recommendation

hold

The Form 4 filing details routine insider transactions, specifically the gifting of shares and the accrual of dividend equivalent rights by the Chairman and CEO. These transactions are part of standard executive compensation and personal financial planning and do not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for a 'buy' or 'sell' decision.

Keywords

LeMaitre Vascular, LMAT, George W. LeMaitre, Insider Trading, SEC Form 4, Stock Disposition, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, CEO Stock Transactions

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.